Cargando…
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation i...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851388/ https://www.ncbi.nlm.nih.gov/pubmed/17274834 http://dx.doi.org/10.1186/bcr1633 |
_version_ | 1782132964757340160 |
---|---|
author | Landgraf, Ralf |
author_facet | Landgraf, Ralf |
author_sort | Landgraf, Ralf |
collection | PubMed |
description | EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation in cancer, and the nuances that differentiate the four human receptors. This review gives an overview of current models of the control of receptor activity with a special emphasis on HER2 and HER3. |
format | Text |
id | pubmed-1851388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-18513882007-04-12 HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks Landgraf, Ralf Breast Cancer Res Review EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation in cancer, and the nuances that differentiate the four human receptors. This review gives an overview of current models of the control of receptor activity with a special emphasis on HER2 and HER3. BioMed Central 2007 2007-01-22 /pmc/articles/PMC1851388/ /pubmed/17274834 http://dx.doi.org/10.1186/bcr1633 Text en Copyright © 2007 BioMed Central Ltd |
spellingShingle | Review Landgraf, Ralf HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
title | HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
title_full | HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
title_fullStr | HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
title_full_unstemmed | HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
title_short | HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
title_sort | her2 therapy. her2 (erbb2): functional diversity from structurally conserved building blocks |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851388/ https://www.ncbi.nlm.nih.gov/pubmed/17274834 http://dx.doi.org/10.1186/bcr1633 |
work_keys_str_mv | AT landgrafralf her2therapyher2erbb2functionaldiversityfromstructurallyconservedbuildingblocks |